Brain connectivity: the missing link between amyloid and clinical symptoms

https://neurodegenerationresearch.eu/survey/brain-connectivity-the-missing-link-between-amyloid-and-clinical-symptoms-2/

Title of study

Brain connectivity: the missing link between amyloid and clinical symptoms

Acronym for cohort

ADNI and Alzheimer Dementia Cohort

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Betty

Name of Principal Investigator - Last name

Tijms

Address of institution -Institution

Vumc

Address of institution - Street address

Boelelaan 1118

Address of institution - City

Amsterdam1081 HZ

Address of institution - Postcode
Country

Netherlands

Website

www.alzheimercentrum.nl

Contact email

b.tijms@vumc.nl

Funding source

ZonMW

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

Study if grey matter connectivity can be measure progression in preclinical and prodromal Alzheimer's disease

Q2b. What distinguishes this case-control study from other studies?

The methodology used to derive predictor variables (i.e., grey matter connectivity) to monitor disease progression.

Q3a. i) Number of publications that involve use of your cohort to date

n/a

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

One paper under review on prediction of time to dementia onset based on baseline grey matter connectivity.

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

50

Q4a. Study criteria: what is the age range of participants at recruitment? To:

90

Q4b. Study criteria: what are the inclusion criteria?

no diagnosis of dementia, amyloid biomarker data available at first visit, longitudinal structural MRI and clinical information available.

Q4c. Study criteria: what are the exclusion criteria?

None

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1-1,000

Q5b. What is the expected number of control participants?

200-500

Q6a. Please describe what measures are used to characterise participants

Clinical diagnosis amyloid biomarker data

Q6b. Are there additional measures for participants with the clinical disorder?

Yes

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If YES please specify

neuropsychological testing

Q7. What is the study design?

Prospective cohort

Q8. Are your cases matched by
Q9a. Does your study includes a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Are data collected

As part of other studies (ADNI and Amsterdam Dementia Cohort)

Q12. Is there a system in place to enable re-contact with patients for future studies?

Yes (participants have given permission to be re-contacted via the PIs)

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

100

Q13a. Please give information on data stored in a database (2)

Database is web-based

% Available

100

Q13a. Please give information on data stored in a database (3)
% Available
Q13a. Please give information on data stored in a database (4)
% Available
Q13a. Please give information on data stored in a database (5)
% Available
Please specify language used
% Available

99

Q13b. Please give information on how data is held as individual records

Data is web-based

% Available

99

Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Access through collaboration with PI only

Q15. What data sharing policy is specified as a condition of use?

No requirement to make data publicly available

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below

Other unsure - adni data

Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Types:
Case Control Studies

Member States:
Netherlands

Diseases:
Alzheimer's disease & other dementias

Years:
2016

Database Categories:
N/A

Database Tags:
N/A